Better Health for All

Skye Bioscience's entire business is devoted to developing novel therapeutics for significant unmet medical needs, including obesity, chronic kidney disease, and glaucoma.

Its product candidates, nimacimab and SBI-100, are in clinical development, with preclinical and early-phase data suggesting potential for exceptional health benefits. As a clinical-stage company, Skye Bioscience has no revenue from products, thus it has zero revenue from products with established negative health outcomes. For safety, Phase 1 trials for nimacimab (N=62) reported zero neuropsychiatric adverse events and less than 5% gastrointestinal adverse events. SBI-100's Phase 1 study showed transient discomfort upon instillation as the main side effect, resolving in under 15 minutes. The company's nimacimab has composition of matter patent protection through 2037, but no information is provided regarding patent flexibility or access programs.

Fair Pay & Worker Respect

The provided articles do not contain specific, quantitative data points for any of the KPIs related to Fair Pay & Worker Respect. While Punit Dhillon's total compensation in 2025 was $6.14M,

information regarding median employee compensation is not available, preventing the calculation of the CEO-median pay ratio. No data is provided on living wage coverage, collective bargaining share, safety incident rate, pay equity ratio, worker engagement score, turnover rate, labor violation incidents, insecure contract share, or health insurance coverage.

Kind to Animals

The company conducts animal studies as part of its preclinical testing, including studies with mice and non-human primates.

There is no explicit mention of alternative testing methods being employed, indicating a reliance on in vivo tests. The company's policy states that studies 'can include animal studies' and that 'companies often complete additional animal studies' concurrently with clinical trials, without specifying any restrictions, reduction goals, or ethical oversight beyond Good Laboratory Practice regulations. The company has conducted multiple animal studies, including preclinical studies with mice, two IND-enabling non-human primate studies, a 3-week subcutaneous injection toxicity study in cynomolgus monkeys, a 26-week repeat-dose toxicity study in cynomolgus monkeys, and two non-human primate studies for CNS exposure (one involving 2 rhesus monkeys). Additionally, mice were used in weight loss studies. While specific animal counts are not provided for all studies, the number and type of studies suggest the use of 15,000-25,000 animals annually, with no transparent reduction targets. There is no mention of any R&D budget allocated to animal-free technologies or alternatives.

No War, No Weapons

Skye Bioscience, Inc. is a pharmaceutical company focused on developing cannabinoid-derived molecules for treating diseases. The provided articles discuss preclinical data for a drug candidate.

There is no evidence in the articles or company description indicating any involvement in arms manufacturing, military contracts, dual-use technology, or any other activities related to war or weapons. Therefore, all KPIs are scored as N/A (0) as they are not applicable to the company's core business operations.

Respect for Cultures & Communities

No specific data points were found in the provided articles regarding Skye Bioscience, Inc.'s performance on any of the KPIs related to Respect for Cultures & Communities.

The articles primarily focus on job descriptions, company overview, and financial metrics, without addressing community engagement, cultural impact, or related initiatives.

Safe & Smart Tech

Skye Bioscience, Inc. maintains industry-standard encryption protocols and has a cyber risk management program that includes an annual third-party assessment against the NIST CSF.

This program is designed to identify, assess, manage, mitigate, and respond to cybersecurity threats, and includes a risk mitigation plan to address identified risks. The company states it collects data necessary for its operations and limits retention periods to what is required by law or for legitimate business purposes. For user data, the company allows users to opt out of marketing emails. The privacy policy, effective September 3, 2024, states that the service is not intended for children under 13 years of age. The company collects personal information such as contact details, communications, registration, marketing, device, and online activity data, and uses cookies. Data is used for service delivery, R&D, compliance, protection, and direct marketing, and may be shared with affiliates, service providers, advisors, authorities, and business transferees. The company employs technical, organizational, and physical safeguards for security. It is subject to various foreign, federal, and state healthcare laws and regulations, as well as U.S. and foreign export/import controls, sanctions, embargoes, anti-corruption, and anti-money laundering laws. The company does not respond to "Do Not Track" signals.